1 / 4

The American College of Cardiology Foundation / American Heart Association

The American College of Cardiology Foundation / American Heart Association. Clopidogrel Recommendations for Practice. Recommendations for Practice. Adherence to existing ACCF/AHA guidelines for the use of antiplatelet therapy should remain the foundation for therapy.

powellt
Download Presentation

The American College of Cardiology Foundation / American Heart Association

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The American College of Cardiology Foundation / American Heart Association Clopidogrel Recommendations for Practice

  2. Recommendations for Practice Adherence to existing ACCF/AHA guidelines for the use of antiplatelet therapy should remain the foundation for therapy. Clinicians must be aware that genetic variability in CYP enzymes alter clopidogrel metabolism, which in turn can affect its inhibition of platelet function. The specific impact of the individual genetic polymorphisms on clinical outcome remains to be determined. Information regarding the predictive value of pharmacogenomic testing is very limited at this time; resolution of this issue is the focus of multiple ongoing studies. David Holmes, et al, ACCF/AHA Clinical Alert , 2010

  3. Recommendations for Practice The evidence base is insufficient to recommend either routine genetic or platelet function testing at the present time. There are several possible therapeutic options for patients who experience an adverse event while taking clopidogrel in the absence of any concern about medication compliance. Alternative dosing strategies or newer antiplatelet drugs could improve platelet inhibition and might be considered. David Holmes, et al, ACCF/AHA Clinical Alert , 2010

  4. Conclusions Because of a lack of evidence-based data, specific recommendations and strategies for routine genetic testing and identification of optimal care strategies cannot be offered at this time. “The evidence base is insufficient to recommend either routine genetic or platelet function testing at the present time. There is no information that routine testing improves outcome in large subgroups of patients. In addition, the clinical course of the majority of patients treated with clopidogrel without either genetic testing or functional testing is excellent. …Careful clinical judgment is required to assess the importance of the variability in response to clopidogrel for an individual patient and its associated risk to the patient.” David Holmes, et al, ACCF/AHA Clinical Alert , 2010

More Related